An Intervention to Reduce Sedentary Behavior for Adults With Chronic Kidney Disease (RESET-CKD)

February 19, 2026 updated by: Mary Hannan, University of Illinois at Chicago

An Intervention to Reduce Sedentary Behavior for Adults With Chronic Kidney Disease: RESET-CKD

RESET-CKD is evaluating an intervention to support Black adults with chronic kidney disease (CKD) to reduce their sedentary (e.g., sitting) time. Half of the participants will be randomized to the intervention, where the goal is to support individuals to reduce their sitting time, and the other half will be randomized to an attention control condition that provides CKD-related education not related to sedentary behavior. All participants will be followed for 12 weeks.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • Illinois
      • Chicago, Illinois, United States, 60612
        • Recruiting
        • UI Health/University of Illinois Chicago
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Self-identifies as Black or African American
  • Age ≥35 to ≤80 years old
  • CKD Stage 1-4
  • Self-reported 6 or more hours/day of sedentary time
  • Ability to speak/read/understand English
  • Has access to a telephone

Exclusion Criteria:

  • Being unable to walk 1 block
  • Being unable to stand from a seated position without assistance
  • Using a wheelchair, walker, or cane for all of their ambulation
  • Presence of a condition(s) or diagnosis, either physical or psychological, that precludes participation, including: Lower-extremity amputation (AKA or BKA) without prosthetic, Orthopedic condition that would preclude prompted sit-to-stand transitions or standing, Neurologic or psychiatric condition that would preclude prompted sit-to- stand transitions or standing, Severe cognitive impairment, Unstable coronary artery disease (i.e., angina with activity), Orthostatic hypotension
  • Kidney transplant
  • Any other condition that the investigator considers precludes participation in the trial
  • Participated in the Patient Advisory Board

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: RESET-CKD
RESET-CKD is a 12-week intervention that consists of four major components to support decreasing sedentary behavior: (1) health coaching, (2) feedback charts on sedentary behavior, (3) a workbook, and (4) reminders and cues.
Behavioral: RESET-CKD
RESET-CKD is a 12-week intervention that consists of four major components to support decreasing sedentary behavior: (1) health coaching, (2) feedback charts on sedentary behavior, (3) a workbook, and (4) reminders and cues.
Active Comparator: Attention Control
CKD-related education
Other: Attention Control
CKD-related education

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in sedentary time
Time Frame: Baseline to week 12
Change in activPAL-measured sedentary time
Baseline to week 12

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in self-reported sedentary time
Time Frame: Baseline to week 12
Change in self-reported sedentary time
Baseline to week 12
Change in health-related quality of life
Time Frame: Baseline to week 12
Change in health-related quality of life measured via the KDQOL
Baseline to week 12

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Illinois at Chicago

Collaborators

National Institute of Nursing Research (NINR)

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 13, 2025

Primary Completion (Estimated)

September 1, 2026

Study Completion (Estimated)

May 1, 2027

Study Registration Dates

First Submitted

December 23, 2024

First Submitted That Met QC Criteria

December 23, 2024

First Posted (Actual)

December 31, 2024

Study Record Updates

Last Update Posted (Actual)

February 23, 2026

Last Update Submitted That Met QC Criteria

February 19, 2026

Last Verified

July 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2024-1410
  • K23NR021034 (U.S. NIH Grant/Contract)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Kidney Disease(CKD)

Clinical Trials on RESET-CKD

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe